Related Experiment Video
Updated: Nov 21, 2025
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
3.9K
Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification.
Fergus Stafford1, Kate Thomson2,3, Alexandra Butters1,4
1Cardio Genomics Program at Centenary Institute, The University of Sydney, Locked Bag 6, Newtown, NSW, 2042, Australia.
Current Cardiology Reports
|January 12, 2021
Summary
Genetic testing advances understanding of hypertrophic cardiomyopathy (HCM). Genetics plays a key role in cascade testing, risk stratification, and future patient management for improved outcomes.
Area of Science:
- Cardiovascular Genetics
- Molecular Pathogenesis
- Genetic Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) was initially considered a purely Mendelian disorder.
- Emerging research identifies distinct HCM sub-groups with varied genetic underpinnings.
- Some HCM cases stem from sarcomere variants, while others arise from genes mimicking HCM.
Purpose of the Study:
- To review the genetic basis of hypertrophic cardiomyopathy (HCM).
- To highlight recent advancements in genetic testing for HCM.
- To explore the role of genetics in risk stratification and management of HCM.
Main Methods:
- Review of current scientific literature on HCM genetics.
- Analysis of recent genetic testing methodologies and their clinical utility.
- Evaluation of the evolving role of genetic information in patient care.
Main Results:
- Genetic testing is valuable for cascade screening in families with HCM.
- Genotype information is increasingly relevant for prognosis and patient management.
- Emerging evidence supports genetics in guiding risk stratification and treatment decisions.
Conclusions:
- Genetic testing is an essential tool in managing hypertrophic cardiomyopathy (HCM).
- Genotype-directed management promises improved outcomes for HCM patients and families.
- Future applications of genetic insights will further refine HCM risk assessment and treatment strategies.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
149
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
149
01:29Cardiomyopathy V: Interprofessional Care
124
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124
01:25Cardiomyopathy I: Introduction and Classification
215
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
215
01:30Cardiomyopathy II: Dilated Cardiomyopathy
152
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
152
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
200
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
200
01:30Heart Failure IV: Classification and Diagnostic Evaluation
135
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
135